Takayuki Katsube

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Urinary Tract Infection

Multidrug Resistant

Recombinant Human

Top Venues

Infectious diseases and therapy

Journal of pharmacokinetics and pharmacodynamics

Antimicrobial agents and chemotherapy

Journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor. Infectious diseases and therapy 13 (3) (2024)
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor. Infectious diseases and therapy 13 (3) (2024)
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor. Infectious diseases and therapy 13 (3) (2024)
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor. Infectious diseases and therapy 13 (3) (2024)
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor. Infectious diseases and therapy 13 (3) (2024)
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor. Infectious diseases and therapy (2024)
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor. Infectious diseases and therapy 13 (3) (2024)
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor. Infectious diseases and therapy (2024)
Nao Kawaguchi, Takayuki Katsube, Roger Echols, Toshihiro Wajima, David P Nicolau
Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Pneumonia Patients and Healthy Subjects. Journal of clinical pharmacology (2021)
Takayuki Katsube, Toshihiro Wajima
Evaluation of covariate effects using variance-based global sensitivity analysis in pharmacometrics. Journal of pharmacokinetics and pharmacodynamics 48 (6) (2021)
Nao Kawaguchi, Takayuki Katsube, Roger Echols, Toshihiro Wajima
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection. Antimicrobial agents and chemotherapy 65 (3) (2021)
Takayuki Katsube, Yuji Inoue, Takahiro Fukuhara, Takeshi Kano, Toshihiro Wajima
Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters. European journal of clinical pharmacology 76 (12) (2020)
Takayuki Katsube, Ryosuke Shimizu, Takahiro Fukuhara, Takeshi Kano, Toshihiro Wajima
Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Clinical pharmacokinetics 58 (11) (2020)